Significant Association of XPD Codon 312 Single Nucleotide Polymorphism with Bladder Cancer Susceptibility in Taiwan

CHAO-HSIANG CHANG1,2,*, ROU-FEN WANG2,*, RU-YIN TSAI2*, HSI-CHIN WU1,2, CHUNG-HSING WANG2, CHIA-WEN TSAI2,3, CHIA-LIN CHANG2, YUNG-AN TSOU2, CHIU-SHONG LIU2,5, and DA-TIAN BAU2,3,4

Departments of 1Urology, and 3Family Medicine, and 2Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung; 3Graduate Institute of Chinese Medical Science, and 4Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C.

Abstract. Background: The DNA repair gene xeroderma pigmentosum group D (XPD), an important caretaker of the overall genome stability, is thought to play a major role in the development of human malignancy. Polymorphic variants of XPD, at codon 312 (rs1799793), 751 (rs13181) and promoter-114 (rs3810366), were chosen to be studied for their association with bladder cancer susceptibility in a central Taiwanese population. Patients and Methods: In this hospital-based case-control study, bladder cancer patients (308) and age- and gender-matched healthy controls (308) were recruited and their genotypes were analyzed by a polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) method. Results: A significant difference in the frequency of the XPD codon 312 genotype, but not the XPD codon 751 or promoter-114 genotypes, was found between the bladder cancer and control groups. Those who had G/A or A/A at XPD codon 312 showed a 1.85-fold (95% confidence interval=1.34-2.56) increased risk of bladder cancer compared to those with G/G. As for XPD codon 312 and promoter-114, there was no difference in distribution between the bladder cancer and control groups. Conclusion: The heterozygous and homozygous A allele of the XPD codon 312 may be responsible for bladder carcinogenesis and useful in the early detection and prediction of bladder cancer.

*These authors contributed equally to this work.

Correspondence to: Da-Tian Bau, Ph.D., Terry Fox Cancer Research Laboratory, China Medical University Hospital, 2 Yuh-Der Road, Taichung, 404 Taiwan, R.O.C. Tel: +886422053366 Ext 3312, Fax: +886422052121 Ext 1511, e-mail: datian@mail.cmuoh.org.tw; artbau1@yahoo.com.tw

Key Words: XPD, single nucleotide polymorphism, bladder cancer, DNA repair.

0250-7005/2009 $2.00+.40
transcription and NER, which removes bulky adducts, such as those caused by environmental agents, UV-induced DNA damage, crosslinks and oxidative damage (11, 12). Mutations in the XPD gene can diminish the helicase activity, resulting in a defect in NER, in transcription and in an abnormal response to apoptosis (13). Single nucleotide polymorphisms (SNPs) have been identified in several exons of the XPD gene, among which one in codon 312 of exon 10 and another in codon 751 of exon 23 are commonly studied and result in amino acid changes (Asp312Asn and Lys751Gln, respectively) (14). These SNPs are associated with lower DNA repair capacity and a higher level of DNA adducts (14,15). Some studies have reported significant associations between the Asp312Asn or Lys751Gln variants and predisposition to many types of cancer, including lung cancer (16), squamous cell carcinoma of the head and neck (17), melanoma (18) and breast cancer (19-22). A few studies have reported that XPD polymorphisms are associated with bladder cancer (23-27), but an investigation of XPD genotypes in bladder cancer in the Taiwanese population is still lacking.

Since DNA repair gene alterations have been shown to cause a reduction in DNA repair capacity, we hypothesized that XPD gene polymorphisms may be risk factors for bladder cancer. To test this hypothesis, DNA samples from bladder cancer patients and healthy controls, in a central Taiwan population were analyzed by a polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) method to determine the genotypic frequency of three SNPs of the XPD gene (Asp312Asn, Lys751Gln and promoter-114). To the best of our knowledge, this is the first study carried out to evaluate these polymorphisms at the same time and in a high prevalence of bladder cancer of Taiwanese population.

Patients and Methods

Study population and sample collection. Three hundred and eight patients diagnosed with bladder cancer were recruited at the outpatient clinics of general surgery between 2001-2008 at the China Medical University Hospital, Taichung, Taiwan, Republic of China. The clinical characteristics were all defined by expert surgeons (Drs. Chang and Wu). All the patients voluntarily participated, completed a self-administered questionnaire and provided peripheral blood samples. An equal number of non-bladder cancer healthy volunteers as controls were selected by matching for age, gender and some indulgences after initial random sampling from the Health Examination Cohort of the hospital. The study was approved by the Institutional Review Board of the China Medical University Hospital and written-informed consent was obtained from all the participants.

Genotyping assays. Genomic DNA was prepared from peripheral blood leukocytes using a QiAamp Blood Mini Kit (Blossom, Taipei, Taiwan) and further processed as described in previous papers (28-35). Briefly, the following primers were used: for XPD Asp312Asn: 5'-TGGCCCTGTCTCTACTTCCTCC-3' and 5'-GACGGGGAGGCGGAAAGGGACT-3'; for XPD Lys751Gln: 5'-ACTTCATAAGACCTCTAGC-3' and 5'-GATTACGGACATCTCCAATG-3' and for XPD promoter-114, 5'-ATGAATATTCAGCGAGAGGC-3' and 5'-CTGGGTTCGATCAATCTCAAT-3'.

The following cycling conditions were used: one cycle at 94°C for 5 min; 35 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 30 s; and a final extension at 72°C for 10 min. The PCR products were studied after digestion with Hpy99I, EarI, and Bme1580I, restriction enzymes for XPD Asp312Asn (cut from 250 bp A type into 188+62 bp G type), Lys751Gln (cut from 326 bp C type into 127+199 bp A type) and promoter -114 (cut from 303 bp G type into 101+202 bp C type), respectively.

Statistical analyses. Only those samples with complete DNA polymorphism data (control/cases=308/308) were selected for final analyzing. To ensure that the controls used were representative of the general population and to exclude the possibility of genotyping error, the deviation of the genotype frequencies of XPD SNPs in the control subjects from those expected under the Hardy-Weinberg equilibrium was assessed using the goodness-of-fit test. Pearson’s Chi-square test or Fisher’s exact test (when the expected number in any cell was less than five) was used to compare the distribution of the XPD genotypes between cases and controls. The cancer risk associated with the genotypes was estimated as odds ratio (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression. The data were recognized as significant when the statistical p-value was less than 0.05.

Results

The frequency of the alleles for the XPD Asp312Asn, Lys751Gln and promoter-114 in the bladder cancer and control groups is shown in Table I. The Asn allele at XPD Asp312Asn was significantly associated with bladder cancer risk (p=0.0001). In contrast, Lys or Gln at XPD Lys751Gln, or the C or G allele at promoter-114, were not differently distributed in the oral cancer patient and control groups (p>0.05).

The frequency of the genotype of XPD Asp312Asn, Lys751Gln and promoter-114 polymorphisms in the bladder cancer and control groups is shown in Table II. Using 312G as the reference group, there was an obvious association between the homozygotes and heterozygotes of 312A of XPD and bladder cancer risk. A combination of the homozygotes (A type) and promoter -114, were not differently distributed in the oral cancer patient and control groups (p>0.05).

Discussion

In this study, the genotype frequency of the A allele at XPD Asp312Asn was significantly higher in the bladder cancer group (34.4%) than in the control group (24.5%) (Table
I). It was also found that participants homozygous for XPD Asp312Asn had a 3.81-fold higher risk of bladder cancer (Table II). As for the Asp/Asn heterozygotes, the risk was almost half of the level, a 1.90-fold increased risk. After combining the heterozygous and homozygous participants in both case and control groups, there was still an obvious increased risk of 1.85-fold (Table II). The data suggested that 312Asn was indeed a marker for bladder cancer in Taiwan. As long as 312Asn was detected, no matter whether as hetero- or homozygote, the carriers were more susceptible to bladder cancer. As for the role of XPD Asp312Asn in bladder carcinogenesis, the present findings were consistent with the previous study, which reported the Asn allele to be a risky genotype and the homozygous Asn/Asn genotype to have a significantly 4.62-fold higher risk than the combined group of hetero- and homozygous Asp with non-muscle-invasive bladder cancer (24). In addition, XPD Asp312Asn has also been reported to be associated with a 1.8-fold increased risk for lung cancer (16) and a 1.84-fold for prostate cancer (30). Interestingly, the two target populations in those studies (Han and Taiwanese) were very close to those here. However, SNP of XPD Asp312Asn have also been reported not to be involved in cancer etiology. We have previously reported that the non-homologous end-joining DNA repair capacities of each person may be associated with their susceptibility to breast cancer (38). Therefore, it would be interesting to investigate differences in NER repair capacities between individuals to preclude chance findings, particularly those among subgroups, and clarify the detail of the mechanisms involved.

In conclusion, in this large population study, focused on the SNPs of XPD and bladder cancer in Taiwan the presence of the A allele of Asp312Asn was associated with a higher risk of bladder cancer. The A allele of Asp312Asn may be a useful marker in bladder oncology for anticancer application and early cancer detection.

Acknowledgements

We appreciate Yung-Shun Kuo, Hua-Shiang Chen, Hui-Ni Cheng, Hsiu-Min Hsieh and TissueBank of China Medical University Hospital for their technical assistance. This study was supported by research grants from the Terry Fox Cancer Research Foundation, China Medical University and Hospital (CMU-97-333) and the National Science Council (NSC 98-2320-B-039-010-MY3).

References


Received May 26, 2009
Revised August 14, 2009
Accepted September 2, 2009